drugset

drugset / Trial / NCT00683059

Single Agent Abraxane as Second Line Therapy in Bladder Cancer

NCT00683059 ↗

Phase 2 Completed 48 enrolled Sunnybrook Health Sciences Centre Celgene Corporation · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine what effects the drug Abraxane has on bladder cancer.

Timeline

Start: 2008-03
Primary completion: 2012-06
Completion: 2012-06

Publications

Ko YJ, Canil CM, Mukherjee SD, Winquist E, Elser C, Eisen A, Reaume MN, Zhang L, Sridhar SS. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol. 2013 Jul;14(8):769-76. doi: 10.1016/S1470-2045(13)70162-1. Epub 2013 May 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Paclitaxel	Small molecule	260 mg/m2	Intravenous

Indications